يعرض 1 - 10 نتائج من 23 نتيجة بحث عن '"Patricia Martin-Regueira"', وقت الاستعلام: 1.10s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN

    المؤلفون: Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

    المصدر: Haematologica, Vol 999, Iss 1 (2024)

    مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

    وصف الملف: electronic resource

    Relation: https://haematologica.org/article/view/11570; https://doaj.org/toc/0390-6078; https://doaj.org/toc/1592-8721

    URL الوصول: https://doaj.org/article/39e1a5de16144c2285b230f79c731665

    Full Text Finder
    أضف إلى المفضلة
  2. 2
    Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

    المؤلفون: Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, Sarah M. Larson, Susanne Saussele, Delphine Rea, François‐Xavier Mahon, Moshe Yair Levy, María Teresa Gómez‐Casares, Michael J. Mauro, Oumar Sy, Patricia Martin‐Regueira, Jeffrey H. Lipton

    المصدر: British Journal of Haematology.

    مصطلحات موضوعية: Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b65b5007d705c9254abfdc9e17c01e6d
    https://doi.org/10.1111/bjh.18883

    View record at Wiley
    أضف إلى المفضلة
  3. 3
    Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

    المؤلفون: Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

    المصدر: Blood. 140:3935-3937

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d7f6ee2c21012cb1bef12aa2cf2250df
    https://doi.org/10.1182/blood-2022-156669

    أضف إلى المفضلة
  4. 4
    Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

    المؤلفون: Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

    المصدر: Blood. 140:9647-9649

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ed883cc6b53f133882b5f14b1b97ebdc
    https://doi.org/10.1182/blood-2022-164444

    أضف إلى المفضلة
  5. 5
    Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

    المؤلفون: Danny V Jeyaraju, Sheida Hayati, Ann Polonskaia, Maryam Alapa, Manuel Ugidos, Andrew Browne, Alberto Risueño, Patrick Hagner, Vikas Gupta, Moshe Talpaz, Christopher Hernandez, Vincent Chia, Patricia Martin-Regueira, Daniel Lopes de Menezes, Ross La Motte-Mohs, Rajasekhar NVS Suragani, Anita K. Gandhi

    المصدر: Blood. 140:3865-3867

    مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::deb3f2b2d4842bc451d82e70336b717c
    https://doi.org/10.1182/blood-2022-166407

    أضف إلى المفضلة
  6. 6
    Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

    المؤلفون: Patricia Martin-Regueira, Amer M. Zeidan, Hartmut Döhner, Jennifer Lord-Bessen, Eytan M. Stein, Shien Guo, Stéphane de Botton, Pau Montesinos, Paresh Vyas, Andre C. Schuh, Andrew H. Wei, Frederik Lersch, Ling Shi, Courtney D. DiNardo, Jing Gong, Clara Chen

    مصطلحات موضوعية: Health related quality of life, Oncology, medicine.medical_specialty, business.industry, Immunology, Azacitidine, Myeloid leukemia, Cell Biology, Hematology, Newly diagnosed, Intensive chemotherapy, Enasidenib, Biochemistry, IDH2, Internal medicine, Medicine, In patient, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1829e0ecc3394389229a1ddea6b4866b
    https://doi.org/10.1182/blood-2021-147601

    أضف إلى المفضلة
  7. 7
    Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

    المؤلفون: Stéphane de Botton, Pau Montesinos, Andre C. Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H. Wei, Hans Ommen, Sergey Semochkin, Hee-Je Kim, Richard A. Larson, Jaime Koprivnikar, Olga Frankfurt, Felicitas Thol, Jörg Chromik, Jenny Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, Maria Belen Vidriales, Vadim Doronin, Hartmut Döhner, Amir T. Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martin-Regueira, Courtney D. DiNardo

    المساهمون: Institut Català de la Salut, [de Botton S] Gustave Roussy, Université Paris-Saclay, Villejeuf, France. [Montesinos P] Hospital Universitari i Politecnic La Fe, Valencia, Spain. [Schuh AC] Princess Margaret Cancer Centre, Toronto, ON, Canada. [Papayannidis C] IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy. [Vyas P] Oxford Biomedical Research Centre and Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom. [Wei AH] The Alfred Hospital, Melbourne, VIC, Australia. Monash University, Melbourne, VIC, Australia. [Salamero O] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Otros calificadores::/uso terapéutico [Otros calificadores], Immunology, Genetic Phenomena::Genetic Variation::Mutation [PHENOMENA AND PROCESSES], Medicaments antineoplàstics - Ús terapèutic, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Cell Biology, Hematology, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Biochemistry, neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES], Anomalies cromosòmiques, Leucèmia mieloide aguda - Aspectes genètics, Leucèmia mieloide aguda - Tractament, Other subheadings::/therapeutic use [Other subheadings], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS]

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3715a5d50e378580e2588f9f261b90de
    https://ora.ox.ac.uk/objects/uuid:f5d7e243-e3f5-4a9c-b91e-69a2fc98cc60

    أضف إلى المفضلة
  8. 8
    The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

    المؤلفون: Rene Swanink, Lambert Busque, Patricia Martin Regueira, Satu Mustjoki, Rebecca B. Klisovic, Dominik Wolf, Joaquin Martinez-Lopez, Juan Carlos Hernández-Boluda, Kimmo Porkka, Jeffrey H. Lipton

    المصدر: Leukemia & Lymphoma. 62:2040-2043

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, 03 medical and health sciences, 0302 clinical medicine, Text mining, hemic and lymphatic diseases, Internal medicine, medicine, Dose escalation, In patient, business.industry, Myeloid leukemia, Hematology, medicine.disease, respiratory tract diseases, 3. Good health, Dasatinib, 030220 oncology & carcinogenesis, Nivolumab, business, Tyrosine kinase, 030215 immunology, Chronic myelogenous leukemia, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::be46f77b4bbaf846a60e482a25fb7ab4
    https://doi.org/10.1080/10428194.2021.1889536

    PDF full text from Publisher
    أضف إلى المفضلة
  9. 9
    AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

    المؤلفون: Courtney D. DiNardo, Stéphane de Botton, Alberto Risueño, Andre C. Schuh, Bob Löwenberg, Hee-Je Kim, Paresh Vyas, Andrew H. Wei, Eytan M. Stein, Hartmut Döhner, Amir T. Fathi, Patricia Martin-Regueira, Lilia Taningco, Iryna Bluemmert, Xin Yu, Wendy L. See, Maroof Hasan

    المصدر: Clinical Lymphoma Myeloma and Leukemia. 22:S249-S250

    مصطلحات موضوعية: Cancer Research, Oncology, Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::378f36a9d79a8130bc59e00dcb3445a6
    https://doi.org/10.1016/s2152-2650(22)01293-9

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  10. 10
    Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

    المؤلفون: Jerald P. Radich, Patricia Martin-Regueira, Huanling Zhu, Dong-Wook Kim, Xiaoli Liu, Qian Jiang, Renuka Gurnani, Andreas Hochhaus, Jianxiang Wang, Michael R. Savona, Giuseppe Saglio, Jorge E. Cortes, Oumar Sy, Jianyu Weng

    المصدر: Leukemia

    مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Myeloid, Adolescent, Epidemiology, Dasatinib, Article, law.invention, Young Adult, Randomized controlled trial, law, hemic and lymphatic diseases, Internal medicine, Clinical endpoint, Humans, Medicine, Prospective Studies, Adverse effect, Prospective cohort study, Aged, Aged, 80 and over, business.industry, Imatinib, Hematology, Middle Aged, medicine.disease, Leukemia, Combination drug therapy, medicine.anatomical_structure, Leukemia, Myeloid, Chronic-Phase, Imatinib Mesylate, Female, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5c674c294992cd9123adf94b9784d9
    https://doi.org/10.1038/s41375-020-0805-1

    Find this article in full text from Springer Verlag. Find this article in full text from ProQuest
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء